{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "VATC" in comments (approximate match)
Status:
US Previously Marketed
Source:
SPOROSTACIN BENZALKONIUM CHLORIDE by ORTHO
(1961)
Source URL:
First marketed in 1921
Class:
MIXTURE
Benzalkonium chloride, also known as BZK, BKC, BAC, alkyldimethylbenzylammonium chloride and ADBAC, is a type of cationic surfactant. It is an organic salt called a quaternary ammonium compound. In 2011, a large clinical trial designed to evaluate the efficacy of hand sanitizers based on different active ingredients in preventing virus transmission amongst schoolchildren was re-designed to exclude sanitizers based on benzalkonium chloride due to safety concerns. Benzalkonium chloride has been in common use as a pharmaceutical preservative and antimicrobial since the 1940s. While early studies confirmed the corrosive and irritant properties of benzalkonium chloride, investigations into the adverse effects of, and disease states linked to, benzalkonium chloride have only surfaced during the past 30 years. Benzalkonium chloride is classed as a Category III antiseptic active ingredient by the United States Food and Drug Administration. Ingredients are categorised as Category III when "available data are insufficient to classify as safe and effective, and further testing is required”. Benzalkonium chloride is excluded from the current United States Food and Drug Administration review of the safety and effectiveness of consumer antiseptics and topical antimicrobial over-the-counter drug products, meaning it will remain a Category III ingredient. The mechanism of bactericidal/microbicidal action is thought to be due to disruption of intermolecular interactions. This can cause dissociation of cellular membrane lipid bilayers, which compromises cellular permeability controls and induces leakage of cellular contents. Other biomolecular complexes within the bacterial cell can also undergo dissociation. Enzymes, which finely control a wide range of respiratory and metabolic cellular activities, are particularly susceptible to deactivation. Critical intermolecular interactions and tertiary structures in such highly specific biochemical systems can be readily disrupted by cationic surfactants. Benzalkonium chloride is a human skin and severe eye irritant. It is a suspected respiratory toxicant, immunotoxicant, gastrointestinal toxicant and neurotoxicant.
Status:
US Previously Marketed
Source:
Amyl Nitrite U.S.P.
(1880)
Source URL:
First marketed in 1880
Source:
Amyl Nitrite U.S.P.
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Abamectin 1.8%
Source URL:
First approved in 2024
Source:
505G(a)(3)
Source URL:
Class:
MIXTURE
Targets:
Conditions:
Abamectin is a mixture of avermectins containing avermectin B1a and avermectin B1b. These two components, B1a and B1b have very similar biological and toxicological properties. The avermectins are insecticidal or anthelmintic compounds derived from the soil bacterium Streptomyces avermitilis. Abamectin is used to control insect and mite pests of a range of agronomic, fruit, vegetable and ornamental crops and it is used by homeowners for control of fire ants. Abamectin acts on insects by interfering with neural and neuromuscular transmission. Abamectin attenuated ethanol-induced gastric ulceration. Chemical structure and effects on GABAARs and P2X4Rs receptor function play key roles in the ability of avermectin to reduce ethanol intake
Status:
Possibly Marketed Outside US
Source:
NCT03237182: Phase 4 Interventional Terminated Tuberculosis, Multidrug-Resistant
(2017)
Source URL:
First approved in 2022
Source:
Kanamycin Sulfates by KDG Impresa LLC, Aqion
Source URL:
Class:
MIXTURE
Targets:
Kanamycin (a mixture of kanamycin A, B and C) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. It is effective against Gram-negative bacteria and certain Gram-positive bacteria. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Serious side effects include tinnitus or loss of hearing, toxicity to kidneys, and allergic reactions to the drug. Mixing of an aminoglycoside with beta-lactam-type antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation. Even when an aminoglycoside and a penicillin-type drug are administered separately by different routes, a reduction in aminoglycoside serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function.
Status:
Possibly Marketed Outside US
First approved in 2010
Source:
ARMOUR THYROID by Rebel Distributors Corp
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 2007
Source:
21 CFR 334
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 2007
Source:
Virginiamycin by Phibro Saúde Animal Internacional Ltda.
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NADA141349
(2013)
Source URL:
First approved in 2005
Source:
NADA141244
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
NCT03177538: Phase 4 Interventional Completed Infertility, Female
(2017)
Source URL:
First approved in 2005
Source:
PLUSET by Minitube of America, Inc.
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
First approved in 1997
Source:
NADA141079
Source URL:
Class:
MIXTURE
Conditions:
Eprinomectin is a mixture of two homologues, eprinomectin B1a (90%) and eprinomectin B1b (10%). The drug is indicated for the treatment of gastrointestinal roundworms in cattle. Eprinomectin acts by binding to glutamate-gated chloride ion channels that leads to paralysis and death of the parasite.